Welcome to our dedicated page for Caribou Biosciences SEC filings (Ticker: CRBU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Caribou Biosciences, Inc. (Nasdaq: CRBU) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including Forms 10-K, 10-Q, 8-K, and other Exchange Act reports. As a clinical-stage CRISPR genome-editing biopharmaceutical company, Caribou uses these filings to report on its financial condition, clinical development progress, and key corporate events.
Current and periodic reports such as Forms 10-Q and 10-K contain management’s discussion of operating results, research and development spending on allogeneic CAR-T programs like vispacabtagene regedleucel (vispa-cel; formerly CB-010) and CB-011, and information about licensing and collaboration revenue. These filings also describe risk factors associated with developing allogeneic CAR-T cell therapies, the company’s dependence on clinical trial outcomes, and its capital resources.
Form 8-K filings are especially relevant for tracking material events at Caribou. Recent 8-Ks have furnished press releases announcing quarterly financial results and business updates, preliminary cash and investment balances, and detailed clinical data from the ANTLER phase 1 trial of vispa-cel and the CaMMouflage phase 1 trial of CB-011. An 8-K dated June 18, 2025, also documents Nasdaq’s notice that Caribou regained compliance with the minimum bid price requirement under Listing Rule 5450(a)(1).
Investors interested in regulatory strategy and designations can use these filings to review discussions of RMAT, Fast Track, and Orphan Drug designations for vispa-cel and CB-011, as well as the company’s description of a planned randomized, controlled pivotal phase 3 trial for vispa-cel in second-line large B cell lymphoma.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly identify important disclosures on clinical data, cash runway, and Nasdaq listing status. Real-time updates from EDGAR, along with access to current and historical 8-Ks and other reports, support deeper analysis of CRBU’s regulatory and financial history.
Caribou Biosciences Chief Medical Officer Tina M. Albertson reported a mix of equity grants and a small tax-related sale. She received 55,000 shares of common stock as restricted stock units that vest annually over four years starting on February 20, 2027. She was also granted an option for 247,500 shares of common stock, vesting monthly so that it is fully vested by February 20, 2030.
Separately, 1,066 common shares were sold at $1.96 per share in a sell-to-cover transaction to satisfy tax withholding on previously vested RSUs under a pre-established Rule 10b5-1 trading plan. After these transactions, she directly holds 68,523 common shares.
Caribou Biosciences director Zheng Ran received an option grant for 45,000 shares of common stock. The option was awarded at an exercise price of $0.00 per share, reflecting a compensatory equity award rather than a market purchase.
According to the vesting terms, one-twelfth of the option shares vest on each monthly anniversary of the February 20, 2026 grant date, so the award will be fully vested by February 20, 2027, as long as Zheng Ran continues providing services to Caribou Biosciences through each vesting date.
Caribou Biosciences, Inc. reported that director Nancy Whiting received a grant of options to purchase 45,000 shares of common stock. The options have an exercise price of $0.00 per share, representing a compensatory award rather than a cash purchase.
According to the terms, one-twelfth of the option grant vests on each monthly anniversary of the grant date and will be fully vested by February 20, 2027, as long as she continues providing service to the company through each vesting date.
Sacks Natalie reported acquisition or exercise transactions in this Form 4 filing.
Caribou Biosciences, Inc. reported that director Natalie Sacks received an option grant to purchase 45,000 shares of common stock. The option was awarded at a price of $0.00 per share, reflecting a no-cost equity award rather than an open-market purchase.
According to the vesting terms, one-twelfth of the option shares will vest on each monthly anniversary of the grant date, so the award will be fully vested by February 20, 2027, assuming she continues providing service to the company through each vesting date.
Caribou Biosciences, Inc. director Dara Richardson-Heron reported receiving an option grant to purchase 45,000 shares of common stock. The option was awarded at an exercise price of $0.0000 per share, reflecting a typical compensatory equity award rather than an open-market transaction.
According to the vesting terms, one-twelfth of the shares subject to this option vest on each monthly anniversary of the February 20, 2026 grant date. The option will be fully vested by February 20, 2027, as long as Richardson-Heron continues to provide service to Caribou Biosciences through each monthly vesting date.
JOHNSON DAVID LEE reported acquisition or exercise transactions in this Form 4 filing.
Caribou Biosciences, Inc. reported that director David Lee Johnson received a grant of 45,000 options to purchase common stock. The options were awarded for no cash consideration and are held directly by Johnson.
According to the vesting terms, one-twelfth of the option shares vest on each monthly anniversary of the February 20, 2026 grant date, so the award will be fully vested by February 20, 2027, as long as Johnson continues providing service to the company through each vesting date.
Caribou Biosciences, Inc. director Andrew Guggenhime received a grant of options to purchase 45,000 shares of the company’s common stock. The options were awarded at an exercise price of $0.00 per share as a form of equity compensation.
According to the vesting terms, one-twelfth of the option grant vests on each monthly anniversary of the grant date, so the entire 45,000-share option will be fully vested by February 20, 2027, as long as Guggenhime continues to provide services to the company through each vesting date.
Caribou Biosciences, Inc. reported that director Scott Braunstein received a grant of options to purchase 45,000 shares of common stock at an exercise price of $0.00 per share. One-twelfth of the options vest monthly and will be fully vested by February 20, 2027, assuming continued service.
Caribou Biosciences, Inc. Chief Financial Officer Sriram Ryali reported equity awards consisting of stock options and restricted stock units. He was granted an option to purchase 247,500 shares of common stock at an exercise price of $0.00 per share.
The option vests over time, with 1/48 of the shares vesting monthly so that it is fully vested by February 20, 2030, contingent on continued service. He also received 55,000 shares of common stock in the form of RSUs that vest in four equal annual installments beginning on February 20, 2027, also subject to continued service, and will be settled in stock within 30 days after each vesting date.
Haurwitz Rachel E. reported acquisition or exercise transactions in this Form 4 filing.
Caribou Biosciences, Inc. reported new equity awards to President and CEO Rachel E. Haurwitz. On February 20, 2026, she was granted an option to purchase 682,500 shares of common stock and 151,700 shares of common stock in the form of restricted stock units (RSUs).
According to the filing, the RSUs vest in four equal annual installments beginning on February 20, 2027, and are settled in stock within 30 days after each vesting date. The stock option vests as to 1/48 of the shares each month so that it is fully vested by February 20, 2030, in each case subject to her continued service.
The document also reports 3,369,395 shares of common stock held indirectly by The City Canyon Family Trust, of which she is a co-trustee with her spouse, in addition to directly held shares.